2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15728S
    Radotinib-d6 2754051-83-5 98%
    Radotinib-d6 is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.
    Radotinib-d6
  • HY-157296
    AChE-IN-47 3033056-55-9 98%
    AChE-IN-47 (compound g17) is a AChE inhibitor with the IC50 of 0.24 μM. AChE-IN-47 inhibits amyloid β peptides self-aggregation. AChE-IN-47 displays neuroprotective effects and effectively suppresses the intracellular accumulation of reactive oxygen species.
    AChE-IN-47
  • HY-157326
    hMAO-B-IN-6 2764830-43-3 98%
    hMAO-B-IN-6 (compound 17d) is a potent and selective inhibitor of hMAO-B with an IC50 of 67.02 nM. hMAO-B-IN-6 significantly improves Scopolamine (HY-N0296)-induced cognitive impairment in AD mice.
    hMAO-B-IN-6
  • HY-157382
    AChE-IN-51 98%
    AChE-IN-51 (compound 8C) is an orally active, non-competitive inhibitor of AChE and BChE (IC50: 84 nM, 97 nM). It also inhibits MMP-2 and amyloid Aβ1-42 aggregates (IC50: 724 nM, 302 nM). AChE-IN-51 has low cytotoxicity and in silico predicted blood-brain barrier permeability. Can be used for research on diseases such as Alzheimer's disease (AD).
    AChE-IN-51
  • HY-157384
    BChE-IN-22 98%
    BChE-IN-22 (compound 5A) is a selective eqBChE inhibitor (IC50: 0.53 μM), has anti-inflammatory and neuroprotective activities. BChE-IN-22 can inhibit cell damage caused by Aβ25-35 (HY-P0128) and improve cognitive dysfunction caused by Scopolamine (HY-N0296).
    BChE-IN-22
  • HY-157400
    hMAO-B-IN-7 2955577-14-5 98%
    hMAO-B-IN-7 (compound 11n) is a potent and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B), with the IC50 value of 0.79±0.05 μM. hMAO-B-IN-7 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research.
    hMAO-B-IN-7
  • HY-157425
    5-HT2CR agonist 1 1216074-15-5 98%
    5-HT2CR agonist 1 (compound 8), a 7-chloro analogue, is a selective 5-HT2CR partial agonist (Emax=71.09%) with an EC50 value of 121.5 nM and no observed activity toward 5-HT2AR or 5-HT2BR. 5-HT2CR agonist 1 exhibits no recruitment activity for β-arrestin and shows low inhibition of hERG at 10 μM.
    5-HT2CR agonist 1
  • HY-157429
    25N-N1-Nap 2865185-31-3 98%
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6 J mice.
    25N-N1-Nap
  • HY-157430
    BET-IN-21 3014815-06-3 98%
    BET-IN-21 (compound 16) is a blood-brain barrier-permeable extra terminal domain (BET) inhibitor with the Ki of 230 nM. BET-IN-21 inhibits microglia activation and has ameliorative effects on experimental autoimmune encephalomyelitis mice.
    BET-IN-21
  • HY-157437
    AChE/BChE-IN-16 98%
    AChE/BChE-IN-16 (compound C7) is a potent cholinesterase (ChE) inhibitor with IC50s of 30 nM and 48 nM for human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE), respectively. AChE/BChE-IN-16 exhibits a remarkable capacity to safeguard PC12 cells against H2O2-induced apoptosis and effectively suppresses the production of reactive oxygen species (ROS).
    AChE/BChE-IN-16
  • HY-157440
    AChE/Aβ-IN-3 98%
    AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation with IC50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease.
    AChE/Aβ-IN-3
  • HY-157441
    AChE/Aβ-IN-4 98%
    AChE/Aβ-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and β-amyloid (Aβ) aggregation, with the IC50 values of 1.72 ± 0.18 μM and 1.42 ± 0.3 μM, respectively. AChE/Aβ-IN-4 plays an impotant role in neurological disorders, such as Alzheimer’s disease.
    AChE/Aβ-IN-4
  • HY-157461
    Glycation-IN-1 3023711-86-3 98%
    Glycation-IN-1 (Compound 3) is an inhibitor of glycosylation reactions, which has a strong inhibitory effect on the synthesis of initial, intermediate, and final products of glycosylation reactions. Glycion-IN-1 can be used in the research of various chronic diseases, such as diabetes, immune inflammation, cardiovascular diseases and neurodegenerative diseases.
    Glycation-IN-1
  • HY-157476
    AChE-IN-53 2807436-94-6 98%
    AChE-IN-53 (Compound I-52) is a potent NMDAR inhibitor, which is a compound with favorable behavioral and neuroprotective effects.
    AChE-IN-53
  • HY-157517
    MAO-B-IN-29 122823-57-8 98%
    MAO-B-IN-29 (compound 9a) is a inhibitor against MAO-B activity.
    MAO-B-IN-29
  • HY-157527
    hAChE-IN-7 2978613-03-3 98%
    hAChE-IN-7 (compound 5s) is a mixed inhibitor affecting both the catalytic active site (CAS) and peripheral anionic site (PAS) of hAChE. hAChE-IN-7 displays the balanced inhibitory effect on hAChE (IC50=69.8 nM) and hBuChE (IC50=68.0 nM), and exhibits inhibitory activity against β-secretase-1 (BACE-1) (IC50=3.6 μM). hAChE-IN-7 has the potential for Alzheimer's disease (AD) research.
    hAChE-IN-7
  • HY-157555
    NLRP3-IN-29 2198483-40-6 98%
    NLRP3-IN-29(Compound 5M) is an inhibitor of NLR family pyrin domain containing 3 (NLRP3). NLRP3-IN-29 has the potential for blood-brain barrier permeability and inflammation inhibition both in vivo and in vitro. NLRP3-IN-29 can be used for research on Alzheimer's disease.
    NLRP3-IN-29
  • HY-157563
    Dopamine D4 receptor ligand 2 219125-63-0 98%
    Dopamine D4 receptor ligand 2 (compound 17) is a potent and selective dopamine D4 ligand with IC50 values of 0.057, >1000, 220, 270 nM for D4, D2, 5-HT1A, α1, respectively.
    Dopamine D4 receptor ligand 2
  • HY-157743
    SCH 60057 203061-35-2 98%
    SCH 60057 (Compound 7) is a neurokinin (NK) receptor inhibitor that can be isolated from Acremonium sp., with IC50 values of 6 μM and 12 μM for NK1 and NK2, respectively.
    SCH 60057
  • HY-157751
    RIPK1-IN-21 3016304-64-3 98%
    RIPK1-IN-21 (Compound I-5) is an inhibitor of RIPK1 with an EC50 value of 14.8 nM. RIPK1-IN-21 can be used in the research of neurodegenerative, autoimmune, and inflammatory diseases.
    RIPK1-IN-21
Cat. No. Product Name / Synonyms Application Reactivity